Background Patients with obesity were underrepresented in studies evaluating the safety
and effectiveness of direct oral anticoagulants (DOAC) in patients with non-valvular atrial …

Background Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …

Background: Despite data derived from observational studies, optimal anticoagulation
strategies have yet to be established for patients with nonvalvular atrial fibrillation and …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Abstract Background/Objectives Adverse bleeding events happened more frequently among
individuals with, or at risk of, a low body mass index (BMI) than others. Despite increasing …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …